By reducing TYK2 activity in animal models, researchers found tau buildup was decreased, suggesting TYK2 inhibitors could be a potential therapeutic pathway. The findings could eventually help prevent ...

Published in Nature Neuroscience, the study suggests that partially restraining TYK2 could be a strategy to reduce tau levels and toxicity. Previous studies showed that tau is chemically modified ...

Published in Nature Neuroscience, the study suggests that partially restraining TYK2 could be a strategy to reduce tau levels and toxicity. “Many studies have shown that the accumulation of tau ...

Published in Nature Neuroscience, the study suggests that partially restraining TYK2 could be a strategy to reduce tau levels and toxicity. "Many studies have shown that the accumulation of tau in ...

Alumis' lead drug, ESK-001, is a potential best-in-class TYK2 inhibitor for treating plaque psoriasis and immunological diseases in general., with phase 3 trial data expected in 1H2026.

(Sorry about that, but we can’t show files that are this big right now.) ...

Working with human cells and animal models of tau-driven dementia, the researchers are the first to show that TYK2's ...

As a non-receptor tyrosine kinase, TYK2 is a member of the JAK kinase family, which is an important kinase on the JAK-STAT signaling pathway and plays an important role in the pathogenesis of ...